Chairpersons:

Willem J. Remme (NL), Dr. B&H

 Europe, America

Irena Mitevska (MK)

 Heart failure burden in Asia and Middle East countries

• Babak Sherif-Kashani (IR)

 Generating Important Insights into the Spectrum and Outcomes of Acute Heart Failure

Across the African Continent: The Results of THESUS-HF II

• Albertino Damasceno (MZ)

Learning Objectives:

Analyze global heart failure trends with a specific focus on the burden in Asia, Middle East,

and African populations; interpret key results from the THESUS-HF II registry; and address regional disparities in

clinical outcomes and research.

Chairpersons:

Koji Hasegawa (JP), Azer Melikov (AZ)

 Optimal sodium and fluid restriction in heart failure patients with chronic kidney

disease

• Gulana Ağayeva (AZ)

 The role of vasopressin antagonists and fluid management in hypervolemic

hyponatremia

• Gulnaz Dadaşova (AZ)

 Approaches cardio-renal-metabolic benefits of SGLT2 inhibitors in HFrEF

• Cheuk Man Yu (Online)

Learning Objectives:

Learning Objectives: Critically evaluate sodium and fluid restriction evidence in CKD patients;

manage hypervolemic hyponatremia using vasopressin antagonists; and integrate the cardio-

renal-metabolic benefits of SGLT2i into HFrEF care.

Coffee Break

Chairpersons:

Khurshıd Fozilov (UZ), Archil Chukhrukidze (GE)

 Metabolic optimization & micronutrient supplementation

******

 Cardiac rehabilitation & precision exercise prescriptions

• Dr. Anna Vachulová (SK)

 AI-Integrated telemonitoring & remote patient management

*******

Learning Objectives:

Identify current (2026) non-pharmacological advances in chronic heart

failure management, explain the clinical rationale and evidence for metabolic optimization

and micronutrient supplementation, apply principles of cardiac rehabilitation and precision

exercise prescription tailored to individual patient profiles, and assess the role of AI-

integrated telemonitoring and remote patient management in improving early detection,

personalized care, and long-term outcomes in chronic heart failure.

Chairpersons:

Willem J Remme (NL), Mehdi Zoghi (TR)

 Case 1: RAAS inhibition under hyperkalemia and renal dysfunction

*****

 Case 2: Right heart failure and advanced mitral/tricuspid regurgitation

• Şefa Şahbazova (AZ)

 Case 3: Refractory congestion and diuretic resistance (Cardiorenal Syndrome)

*****

Learning Objectives:

At the conclusion of this session, participants will be able to identify

current (2026) non-pharmacological advances in chronic heart failure management,

explain the clinical rationale and evidence for metabolic optimization and micronutrient

supplementation, apply principles of cardiac rehabilitation and precision exercise

prescription tailored to individual patient profiles, and assess the role of AI-integrated

telemonitoring and remote patient management in improving early detection, personalized

care, and long-term outcomes in chronic heart failure

Lunch Break

Chairpersons:

Yury Belenkov (RU), Babak Sherif-Kashani (IR)

 Beta-Blockers in HFpEF: Is Chronotropic Incompetence More Crucial Than Rate

Control?

• Jemil Babayev Akif (AZ)

 Statins in Heart Failure: Pleiotropic benefits versus the “Statin Paradox” in advanced

stages.

• Rahima Gabulova (AZ)

 Digoxin: A relic of the past or an essential tool for symptom and hospitalization

management?

• Emin Allahverdiyev (AZ)

Learning Objectives:

At the conclusion of this session, participants will be able to evaluate

the evolving role of traditional heart failure medications in the era of foundational

quadruple therapy, analyze the clinical evidence for maintaining or adjusting beta-blocker

and statin dosages in various heart failure phenotypes, determine the appropriate clinical

scenarios for the continued use of digoxin for refractory symptoms, and integrate classical

pharmacological principles with modern digital monitoring tools to optimize long-term

patient safety and therapy adherence.

Coffee Break

Chairpersons:

Altay Quliyev (AZ), Isakh Mustafayev (AZ)

 Heart Failure Guidelines in 2026: What is clear, what is controversial?

• Babak Sherif-Kashani (IR)

 Advanced heart Ffilure and vulnerable populations: The grey zones of care

• Yury Belenkov (RU)

 The failing heart and its partners: Cardio–Renal, Cardio–Metabolic, and Multi-Organ

Interactions

• Cengiz Şabanoğlu (TR)

Learning Objectives:

Assess the 2026 heart failure guideline recommendations and

distinguish areas of clear evidence from ongoing controversy, recognize the challenges of

managing advanced heart failure and vulnerable patient populations in real-world practice,

and understand how heart–organ interactions—particularly cardio–renal and cardio–

metabolic syndromes—impact prognosis, treatment selection, and personalized care

strategies beyond standard guideline-based approaches

Chairpersons:

Kamran Musayev (AZ), Firdovsi İbrahimov (AZ)

 Management strategies for acute decompensated advanced HF

•  Yalçın Velibey (TR)

 Ischemic Cardiomyopathy: GDMT alone or in combination with revascularization?

• Reşad Mahmudov (AZ)

Learning Objectives:

Formulate management protocols for acute decompensated advanced

heart failure; and compare the benefits of revascularization versus GDMT alone in ischemic

cardiomyopathy.